TIACCI, Enrico
 Distribuzione geografica
Continente #
NA - Nord America 1485
EU - Europa 1162
AS - Asia 209
Continente sconosciuto - Info sul continente non disponibili 2
SA - Sud America 2
Totale 2860
Nazione #
US - Stati Uniti d'America 1483
IT - Italia 552
UA - Ucraina 218
SE - Svezia 132
VN - Vietnam 127
RU - Federazione Russa 63
FI - Finlandia 62
CN - Cina 48
DE - Germania 38
FR - Francia 24
GB - Regno Unito 22
TR - Turchia 20
BE - Belgio 16
CH - Svizzera 12
AT - Austria 7
PL - Polonia 7
UZ - Uzbekistan 5
GR - Grecia 4
LB - Libano 4
IN - India 3
EC - Ecuador 2
NL - Olanda 2
A2 - ???statistics.table.value.countryCode.A2??? 1
BG - Bulgaria 1
CA - Canada 1
CZ - Repubblica Ceca 1
ES - Italia 1
EU - Europa 1
IR - Iran 1
JP - Giappone 1
MX - Messico 1
Totale 2860
Città #
Chandler 426
Perugia 260
San Mateo 227
Dong Ket 127
Altamura 98
Jacksonville 97
Medford 93
Princeton 91
Lawrence 76
Ann Arbor 75
Wilmington 64
Andover 62
Des Moines 44
Beijing 38
Redmond 28
Saint Petersburg 25
Rome 21
Izmir 19
Norwalk 18
Brussels 16
Woodbridge 15
San Paolo di Civitate 13
Terni 12
Redwood City 10
Dearborn 7
Houston 7
Moscow 7
Falls Church 6
Ashburn 4
Boardman 4
Chicago 4
Duncan 4
Foligno 4
Helsinki 4
Lausanne 4
Kraków 3
Prata Di Pordenone 3
Scafa 3
Den Haag 2
Guangzhou 2
Guayaquil 2
Ivrea 2
Nanning 2
San Diego 2
Allentown 1
Auburn Hills 1
Cambridge 1
Collegeville 1
Faenza 1
Frankfurt Am Main 1
Fremont 1
Fuzhou 1
Hangzhou 1
Hyderabad 1
Kagoya 1
Kocaeli 1
Los Angeles 1
Madrid 1
Milan 1
Montignoso 1
Nanjing 1
Ottawa 1
Paris 1
Philadelphia 1
San Giuliano Milanese 1
Serio 1
Shanghai 1
Todi 1
Tong 1
Valle 1
Wayne 1
Totale 2058
Nome #
Arsenic trioxide and all-trans retinoic acid target NPM1 mutant oncoprotein levels and induce apoptosis in NPM1-mutated AML cells 85
Mutated nucleophosmin detects clonal multilineage involvement in acute myeloid leukemia: Impact on WHO classification 77
Convergent mutations and kinase fusions lead to oncogenic STAT3 activation in anaplastic large cell lymphoma 76
Acute myeloid leukemia with mutated nucleophosmin (NPM1): is it a distinct entity? 71
Acute myeloid leukemia bearing cytoplasmic nucleophosmin (NPMc+AML) shows a distinct gene expression profile characterized by up-regulation of genes involved in stem-cell maintenance 64
Pervasive mutations of JAK-STAT pathway genes in classical Hodgkin lymphoma 61
Simple diagnostic assay for hairy cell leukaemia by immunocytochemical detection of annexin A1 (ANXA1). 58
Targeting Mutant BRAF in Relapsed or Refractory Hairy-Cell Leukemia 57
Tumor protein D52 (TPD52): a novel B-cell/plasma-cell molecule with unique expression pattern and Ca(2+)-dependent association with annexin VI. 56
ARSENIC TRIOXIDE AND ALL-TRANS-RETINOIC ACID TARGET NPM1 MUTANT ONCOPROTEIN LEVELS AND INDUCE APOPTOSIS IN NPM1-MUTATED AML CELLS 55
A microRNA signature specific for hairy cell leukemia and associated with modulation of the MAPK-JNK pathways. 53
Mutational landscape of AML with normal cytogenetics: biological and clinical implications 53
Evolving concepts in the pathogenesis of hairy-cell leukaemia. 50
The NPM1 wild-type OCI-AML2 and the NPM1-mutated OCI-AML3 cell lines carry DNMT3A mutations. 50
Analyzing primary Hodgkin and Reed-Sternberg cells to capture the molecular and cellular pathogenesis of classical Hodgkin lymphoma. 50
Genomics of Hairy cell leukemia 50
Blastic plasmacytoid dendritic cell neoplasm and chronic myelomonocytic leukemia: a shared clonal origin 49
IRTA1 is selectively expressed in nodal and extranodal marginal zone lymphomas. 48
High-Risk Clonal Hematopoiesis as the Origin of AITL and NPM1-Mutated AML 48
Primary Burkitt's lymphoma of bladder in patient with AIDS. 47
Absence of BRAF-V600E in the human cell lines BONNA-12, ESKOL, HAIR-M, and HC-1 questions their origin from hairy cell leukemia. 47
Aspects of gene expression in B cell lymphomas 44
BRAF mutations in hairy-cell leukemia. 43
BRAF V600E mutation in hairy cell leukemia: From bench to bedside 43
The BRAF-V600E mutation in hematological malignancies: a new player in hairy cell leukemia and Langerhans cell histiocytosis. 42
Aberrant subcellular expression of nucleophosmin and NPM-MLF1 fusion protein in acute myeloid leukaemia carrying t(3;5): a comparison with NPMc+ AML. 41
Constant activation of the RAF-MEK-ERK pathway as a diagnostic and therapeutic target in hairy cell leukemia. 40
Immunohistochemistry predicts nucleophosmin (NPM) mutations in acute myeloid leukemia 39
Aberrant somatic hypermutation in tumor cells of nodular-lymphocyte-predominant and classic Hodgkin lymphoma. 39
ALK signaling and target therapy in anaplastic large cell lymphoma 39
Whole-Exome Sequencing Identifies Recurrent Mutations of BCOR in Acute Myeloid Leukemia with Normal Karyotype 39
Whole-exome sequencing identifies somatic mutations of BCOR in acute myeloid leukemia with normal karyotype 38
The authors reply 38
Gene expression profiling of isolated tumour cells from anaplastic large cell lymphomas: insights into its cellular origin, pathogenesis and relation to Hodgkin lymphoma. 38
Choroidal vasculature analysis in MEK inhibitor-associated retinopathy 38
Hairy Cell Leukemia Biomarkers and Methods of Using Same 37
Improved achiral and chiral hplc-uv analysis of ruxolitinib in two different drug formulations 37
Gene expression profiling of hairy cell leukemia reveals a phenotype related to memory B cells with altered expression of chemokine and adhesion receptors 35
T-bet-positive and IRTA1-positive monocytoid B cells differ from marginal zone B cells and epithelial-associated B cells in their antigen profile and topographical distribution. 35
The human NPM1 mutation A perturbs megakaryopoiesis in a conditional mouse model. 35
Dactinomycin induces complete remission associated with nucleolar stress response in relapsed/refractory NPM1-mutated AML 35
THE BRAF-MEK-ERK PATHWAY IN HAIRY CELL LEUKEMIA: A COMPREHENSIVE DISSECTION IN PRIMARY LEUKEMIC CELLS OF ITS BIOLOGICAL AND THERAPEUTIC RELEVANCE 34
Origin and pathogenesis of nodular lymphocyte-predominant Hodgkin lymphoma as revealed by global gene expression analysis. 33
Simple genetic diagnosis of hairy cell leukemia by sensitive detection of the BRAF-V600E mutation. 33
Immunohistochemical surrogates for genetic alterations of CCDN1, PML, ALK, and NPM1 genes in lymphomas and acute myeloid leukemia. 33
The genetics of nodal marginal zone lymphoma 33
High-risk clonal hematopoiesis as the origin of AITL and NPM1-mutated AML 33
A case of concomitant chronic lymphocytic leukaemia and hairy cell leukaemia evaluated for IGHV-D-J rearrangements and BRAF-V600E mutation: lack of evidence for a common origin 32
New treatment options in hairy cell leukemia with focus on BRAF inhibitors 32
Mouse models of NPM1-mutated acute myeloid leukemia: biological and clinical implications 30
THE BRAF INHIBITOR VEMURAFENIB IS SAFE AND HIGHLY EFFECTIVE IN REFRACTORY AND RELAPSED HAIRY CELL LEUKEMIA: RESULTS OF THE HCL-PG01 PHASE-2 ITALIAN CLINICAL TRIAL 30
A novel patient-derived tumorgraft model with TRAF1-ALK anaplastic large-cell lymphoma translocation 30
New classification of acute myeloid leukemia and precursor-related neoplasms: changes and unsolved issues. 29
Constant Activation of the RAF-MEK-ERK Pathway As a Diagnostic and Therapeutic Target in Hairy Cell Leukemia. 29
Consensus guidelines for the diagnosis and management of patients with classic hairy cell leukemia 29
Improved Achiral and Chiral HPLC-UV Analysis of Ruxolitinib in Two Dierent Drug Formulations 29
Safety and efficacy of the BRAF inhibitor dabrafenib in relapsed or refractory hairy cell leukemia: a pilot phase-2 clinical trial 29
PAX5 expression in acute leukemias: higher B-lineage specificity than CD79a and selective association with t(8;21)-acute myelogenous leukemia 28
BRAF inhibitors reverse the unique molecular signature and phenotype of hairy cell leukemia and exert potent antileukemic activity 28
IRTA1+ monocytoid B cells in reactive lymphadenitis show a unique topographic distribution and immunophenotype and a peculiar usage and mutational pattern of IgVH genes. 28
The corepressors BCOR and BCORL1: two novel players in acute myeloid leukemia. 27
Lymphoma 26
Identification of a new subclass of ALK negative ALCL expressing aberrant levels of ERBB4 transcripts 26
Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype 26
Biological and therapeutic relevance of the BRAF-MEK-ERK pathway in hairy cell leukemia 26
The Kruppel-like factor 2 transcription factor gene is recurrently mutated in splenic marginal zone lymphoma 26
Haploidentical peripheral-blood stem-cell transplantation for ALK-positive anaplastic large-cell lymphoma. 25
A BRAF-mutated case of hairy cell leukaemia lacking Annexin-A1 expression 25
Mutations in the genes coding for the NF-κB regulating factors IκBα and A20 are uncommon in nodular lymphocyte-predominant Hodgkin's lymphoma. 24
Identification and Characterization of Novel Rare Nucleophosmin (NPM1) Gene Mutations in Acute Myeloid Leukemia (AML) By a Combinatorial Approach of Immunohistochemistry and Molecular Analyses 24
High expression of several tyrosine kinases and activation of the PI3K/AKT pathway in mediastinal large B cell lymphoma reveals further similarities to Hodgkin lymphoma. 23
Transformation of IGHV4-34+ hairy cell leukaemia-variant with U2AF1 mutation into a clonally-related high grade B-cell lymphoma responding to immunochemotherapy 23
Dissecting Clonal Hematopoiesis in Tissues of Classical Hodgkin Lymphoma Patients 23
Identification of candidate tumour suppressor gene loci for Hodgkin and Reed-Sternberg cells by characterisation of homozygous deletions in classical Hodgkin lymphoma cell lines. 22
Hairy cell leukaemia mimicking multiple myeloma 22
Frequent traces of EBV infection in Hodgkin and non-Hodgkin lymphomas classified as EBV-negative by routine methods: expanding the landscape of EBV-related lymphomas [Tiacci and Lazzi are co-senior authors] 22
Gene dosage effects in chronic lymphocytic leukemia. 21
Human CD30+ B cells represent a unique subset related to Hodgkin lymphoma cells 18
SAVI: a statistical algorithm for variant frequency identification. 17
[Global gene expression analysis and novel signalling pathways in Hodgkin lymphoma] 17
How I treat refractory/relapsed hairy cell leukemia with BRAF inhibitors 17
Subclonal evolution of a classical Hodgkin lymphoma from a germinal center B-cell-derived mantle cell lymphoma. [Tiacci, Mecucci and Kueppers are co-senior authors] 16
Identification of novel STAT5B mutations and characterization of TCRβ signatures in CD4+ T-cell large granular lymphocyte leukemia 15
A curious novel combination of nucleophosmin (Npm1) gene mutations leading to aberrant cytoplasmic dislocation of npm1 in acute myeloid leukemia (aml) 14
Novel NPM1 exon 5 mutations and gene fusions leading to aberrant cytoplasmic nucleophosmin in AML 14
Vemurafenib plus rituximab in refractory or relapsed hairy-cell leukemia 14
Anaplastic large-cell lymphoma 11
Hairy cell leukemia and COVID-19 adaptation of treatment guidelines 7
Vemurafenib and rituximab in patients with hairy cell leukemia previously treated with moxetumomab pasudotox 7
The current role of interferon in hairy cell leukaemia: clinical and molecular aspects 6
Vemurafenib plus Rituximab in Refractory or Relapsed Hairy-Cell Leukemia 3
Genetics of classical Hodgkin Lymphoma [Educational Program of the 23th Congress of the European Hematology Association] 3
Overlapping features of therapy-related and de novoNPM1-mutated AML 2
Novel NPM1 exon 5 mutations and gene fusions leading to aberrant cytoplasmic nucleophosmin in AML 2
Acute myeloid leukemia development soon after anti-CD19 chimeric antigen receptor T-cell infusion in a patient with refractory diffuse large B-cell lymphoma and pre-existing clonal hematopoiesis 2
Totale 3158
Categoria #
all - tutte 6934
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 6934


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2017/201843 0000 00 49 14385
2018/2019134 2169 1633 142 174282
2019/2020286 116254 2811 358 4193915
2020/2021698 7371439 18836 3043 1032345133
2021/2022955 16162421 268 12235 7275197127
2022/2023803 9928318119 111158 150 0000
Totale 3158